Month: September 2022

TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) (OTCQX:VHIBF) is pleased to announce two new licensing agreements of it’s prEDict solution to Stevenson Memorial Hospital (“SMH”) and Georgian Bay General Hospital (“GBGH”), both in Ontario. Stevenson Memorial Hospital (Alliston) has signed a 5-year term and Georgian Bay General Hospital (Midland) has signed a 3-year term, with two optional 1-year extension periods. prEDict is an emergency department (ED) wait time clock, that accurately broadcasts wait times to the community via the hospital website. This unprecedented period in healthcare is currently being made more complicated by staffing issues and higher acuity patients. With emergency departments across the country under significant and severe pressure, communicating ED wait...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, British Columbia, Sept. 29, 2022 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (CSE:VST) (OTC:VSQTF) (“VST” or the “Company”) is pleased to announce that further to the letter of intent entered into on June 23, 2022 (the “LOI”) with 1288273 B.C. Ltd. (“AcquisitionCo“) and Draft Label Technologies Inc. (“Draft Label”), a wholly-owned subsidiary of the Company, the Company has entered into a share exchange agreement effective on September 28, 2022, with AcquisitionCo and Draft Label (the “Share Exchange Agreement”), in respect of a business combination pursuant to which AcquisitionCo will acquire all of the equity interests of Draft Label and the shareholders of Draft Label will receive shares of AcquisitionCo...

Company also earns FDA Fast Track designation for vilobelimab to treat critically ill COVID-19 patients EUA submission based on Phase III results in critically ill COVID-19 patients, recently published in The Lancet Respiratory Medicine Request for EUA follows encouraging interactions with FDA in Type B meeting “Gohibic” conditionally accepted by FDA as proprietary name for vilobelimabJENA, Germany, Sept. 29, 2022 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today submitted a request for Emergency Use Authorization (EUA) following encouraging interactions with the US Food and Drug Administration (FDA) at a Type B meeting held this summer. Additionally, InflaRx has been granted Fast Track designation from...

GlobeAir to serve Southern France and Italy with the Lilium Jet Lilium N.V. (NASDAQ: LILM) (“Lilium”), developer of the first all-electric vertical take-off and landing (“eVTOL”) jet, has announced a partnership with GlobeAir. Under the agreement, GlobeAir intends to purchase 12 Lilium Jets to provide premium and business eVTOL flights to its customer base in the French Riviera and Italy.MONACO, Sept. 29, 2022 (GLOBE NEWSWIRE) — Lilium N.V. (NASDAQ: LILM) (“Lilium”), developer of the first all-electric vertical take-off and landing (“eVTOL”) jet, has announced a partnership with GlobeAir. Under the agreement, GlobeAir intends to purchase 12 Lilium Jets to provide premium and business eVTOL flights to its customer base in the French Riviera and Italy. GlobeAir is Europe’s leading and award-winning private jet operator offering...

NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that, following a Type A meeting with the U.S. Food and Drug Administration (FDA), it intends to resubmit its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine in the third quarter of 2023. The purpose of the Type A meeting was to obtain the FDA’s feedback and agreement on the Company’s plan to address the issues raised in the previously received Complete Response Letter (CRL) to support a resubmission of the AXS-07 NDA. The issues principally related to chemistry, manufacturing, and controls (CMC) considerations. Based on the FDA feedback, the Company will include new CMC information,...

Ress Life Investments A/SHolbergsgade 14, 2 tvDK-1057 Copenhagen KDenmarkCVR nr. 33593163www.resslifeinvestments.comTo: Nasdaq CopenhagenDate: 29 September 2022 Corporate Announcement 33/2022 Ress Life Investments A/S announces capital increase. The Board of Directors in Ress Life Investments A/S has today resolved to utilise its authorisation in article 4.8 of the articles of association to increase the company’s share capital with nominally EUR 984,000 by issuance of 1,968 new shares with a nominal value of EUR 500 each at a price of EUR 2371.13 per share of EUR 500 without pre-emption rights for the company’s existing shareholders. After the capital increase, the registered share capital of the company is EUR 80,982,000 divided into 161,964 shares of EUR 500 nominal value each. Each share of nominal EUR 500 carries one vote...